Show simple item record

dc.contributor.authorSoliz, J
dc.contributor.authorSchneider-Gasser, EM
dc.contributor.authorArias-Reyes, C
dc.contributor.authorAliaga-Raduan, F
dc.contributor.authorPoma-Machicao, L
dc.contributor.authorZubieta-Calleja, G
dc.contributor.authorFuruya, W
dc.contributor.authorTrevizan-Bau, P
dc.contributor.authorDhingra, RR
dc.contributor.authorDutschmann, M
dc.date.accessioned2020-12-15T22:56:41Z
dc.date.available2020-12-15T22:56:41Z
dc.date.issued2020-08-01
dc.identifierpii: S1569-9048(20)30134-8
dc.identifier.citationSoliz, J., Schneider-Gasser, E. M., Arias-Reyes, C., Aliaga-Raduan, F., Poma-Machicao, L., Zubieta-Calleja, G., Furuya, W., Trevizan-Bau, P., Dhingra, R. R. & Dutschmann, M. (2020). Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?. RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 279, https://doi.org/10.1016/j.resp.2020.103476.
dc.identifier.issn1569-9048
dc.identifier.urihttp://hdl.handle.net/11343/254321
dc.description.abstractA very recent epidemiological study provides preliminary evidence that living in habitats located at 2500 m above sea level (masl) might protect from the development of severe respiratory symptoms following infection with the novel SARS-CoV-2 virus. This epidemiological finding raises the question of whether physiological mechanisms underlying the acclimatization to high altitude identifies therapeutic targets for the effective treatment of severe acute respiratory syndrome pivotal to the reduction of global mortality during the COVID-19 pandemic. This article compares the symptoms of acute mountain sickness (AMS) with those of SARS-CoV-2 infection and explores overlapping patho-physiological mechanisms of the respiratory system including impaired oxygen transport, pulmonary gas exchange and brainstem circuits controlling respiration. In this context, we also discuss the potential impact of SARS-CoV-2 infection on oxygen sensing in the carotid body. Finally, since erythropoietin (EPO) is an effective prophylactic treatment for AMS, this article reviews the potential benefits of implementing FDA-approved erythropoietin-based (EPO) drug therapies to counteract a variety of acute respiratory and non-respiratory (e.g. excessive inflammation of vascular beds) symptoms of SARS-CoV-2 infection.
dc.languageEnglish
dc.publisherELSEVIER
dc.titleCoping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
dc.typeJournal Article
dc.identifier.doi10.1016/j.resp.2020.103476
melbourne.affiliation.departmentFlorey Department of Neuroscience and Mental Health
melbourne.source.titleRespiratory Physiology and Neurobiology
melbourne.source.volume279
melbourne.elementsid1453710
melbourne.openaccess.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275159/
melbourne.openaccess.statusPublished version
melbourne.contributor.authorDutschmann, Mathias
dc.identifier.eissn1878-1519
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record